SCHEMBL13868628

SCHEMBL13868628

COc1ccc(-c2cc3c4c(c5c(c3cc2OC)OC(c2ccc(OC)cc2)(c2ccc(N3CCOCC3)cc2)C=C5)C2(CC(C)(C)CC(C)(C)C2)c2ccccc2-4)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 4/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
FYN P06241 1/20 0.32
STK10 O94804 1/20 0.32
SLK Q9H2G2 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
AKT1 P31749 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVR1 Q04771 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13868685 1.00 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL10292860 1.00 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL13868686 0.99 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL12189458 0.99 PRKDC (0.33) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL13868669 0.98 TTK (0.33) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL13868648 0.97 PRKDC (0.33) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL10292675 0.97 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL10263102 0.97 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL13868696 0.97 PRKDC (0.34) PRKDCMEN1KMT2AKDM4EALDH1A1
SCHEMBL13868631 0.96 PRKDC (0.32) PRKDCMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
EP-1674460-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2009-01-21 EP disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070215844-A1 Chromene Compound CRY2, TYR, CRY1 PRKDC 3723/4885MEN1 925/4885KMT2A 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.